With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

New research indicates that high levels of folate and vitamin B12 may elevate prostate cancer risk, particularly for ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...